Department of Pharmacy Practice, Clinical and Administrative Sciences, College of Pharmacy, University of Oklahoma, 4502 East 41st Street, Tulsa, OK 74135-2512, USA.
Am J Health Syst Pharm. 2010 Aug 15;67(16):1344-50. doi: 10.2146/ajhp090477.
The implications of potential false-positive urine drug screen (UDS) results for patients receiving commonly prescribed medications were evaluated.
A comprehensive literature review was conducted to identify false-positive UDSs associated with all clinic formulary medications, as well as common nonprescription medications. The references of each report describing a medication whose use was associated with false-positive UDS results were also reviewed. If a class effect was suspected, additional agents in the category were searched. A total of 25 reports of false-positive UDS results were identified. Categories of medications included antihistamines, antidepressants, antibiotics, analgesics, antipsychotics, and nonprescription agents. Reports of false-positive results were found for the following formulary and nonprescription medications: brompheniramine, bupropion, chlorpromazine, clomipramine, dextromethorphan, diphenhydramine, doxylamine, ibuprofen, naproxen, promethazine, quetiapine, quinolones (ofloxacin and gatifloxacin), ranitidine, sertraline, thioridazine, trazodone, venlafaxine, verapamil, and a nonprescription nasal inhaler. False-positive results for amphetamine and methamphetamine were the most commonly reported. False-positive results for methadone, opioids, phencyclidine, barbiturates, cannabinoids, and benzodiazepines were also reported in patients taking commonly used medications. The most commonly used tests to screen urine for drugs of abuse are immunoassays, even though false-positive results for drugs of abuse have been reported with a number of these rapid-screening products. Results from such tests should be confirmed using additional analytical methods, including gas chromatography-mass spectrometry.
A number of routinely prescribed medications have been associated with triggering false-positive UDS results. Verification of the test results with a different screening test or additional analytical tests should be performed to avoid adverse consequences for the patients.
评估接受常用药物治疗的患者尿液药物筛选(UDS)出现假阳性结果的潜在影响。
对与所有临床处方药物以及常见非处方药物相关的 UDS 假阳性结果进行了全面文献回顾。还回顾了描述与 UDS 假阳性结果相关的药物使用情况的每一份报告的参考文献。如果怀疑存在类别效应,则会对该类别中的其他药物进行搜索。共确定了 25 份与 UDS 假阳性结果相关的报告。药物类别包括抗组胺药、抗抑郁药、抗生素、镇痛药、抗精神病药和非处方药物。在以下处方和非处方药物中发现了假阳性结果报告:溴苯那敏、安非他酮、氯丙嗪、氯米帕明、右美沙芬、苯海拉明、多西拉敏、布洛芬、萘普生、异丙嗪、喹硫平、氟喹诺酮(氧氟沙星和加替沙星)、雷尼替丁、舍曲林、硫利达嗪、曲唑酮、文拉法辛、维拉帕米和非处方鼻腔吸入器。安非他命和苯丙胺的假阳性结果最为常见。在接受常用药物治疗的患者中,还报告了美沙酮、阿片类药物、苯环利定、巴比妥类药物、大麻素和苯二氮䓬类药物的假阳性结果。目前,用于筛查尿液中滥用药物的最常用测试是免疫分析法,尽管许多快速筛选产品都报告了滥用药物的假阳性结果。应使用包括气相色谱-质谱法在内的其他分析方法对这些测试结果进行确认。
许多常规处方药物已被证实与触发 UDS 假阳性结果有关。应使用不同的筛选测试或其他分析测试对测试结果进行验证,以避免对患者产生不良后果。